HeartBeam, Inc. (BEAT)

HeartBeam's stock has been impacted by several key events over the past six months. The company received FDA clearance for its 12-lead ECG synthesis software in December 2025, leading to a stock price surge. In November 2025, HeartBeam reported its Q3 results, highlighting progress towards commercial readiness. In March 2026, HeartBeam reported its Q4 and full-year 2025 results, showing a net loss. The company also announced its first commercial partnership with ClearCardio™, a strategic collaboration with the Icahn School of Medicine at Mount Sinai for AI-ECG algorithms, and the enrollment of the first patients in its Heart Attack Detection Pilot Study (ALIGN-ACS). Despite these positive developments, HeartBeam shares have experienced a significant decline.

Information regarding specific demand seasonality for HeartBeam's products and services is not explicitly detailed. The broader market for mobile ECG devices is projected for significant growth, indicating a strong overall demand rather than pronounced seasonal fluctuations. The company's current focus appears to be on market entry and adoption of its newly cleared technologies rather than managing seasonal demand variations.

HeartBeam is a medical technology company focused on transforming the detection and monitoring of critical cardiac conditions outside traditional healthcare facilities. The company develops and commercializes advanced ECG solutions, including the HeartBeam System, a cable-free, credit card-sized 3D ECG recording device. They also have 12-Lead ECG Synthesis Software, which synthesizes a 12-lead ECG from the 3D signals for arrhythmia assessment, and are developing an Extended-Wear 12-Lead ECG Patch. HeartBeam is also collaborating with the Icahn School of Medicine at Mount Sinai to develop next-generation AI-ECG algorithms.

HeartBeam is headquartered in Santa Clara, California, and has initiated its regional commercial launch in the United States, specifically targeting Southern California and South Florida, with plans for broader national expansion. Internationally, HeartBeam has commenced the Align ACS pilot study in Europe for heart attack detection.

HeartBeam has built a positive brand reputation in the medical technology and cardiac diagnostics space. The company was recognized as a global IP and technology leader in portable cardiac diagnostics and received the 2025 Innovation Award in Remote Cardiac Diagnostics. FDA clearances for its 3D ECG technology and 12-lead ECG synthesis software have bolstered its reputation. The strategic collaboration with the Icahn School of Medicine at Mount Sinai further enhances its standing. Analyst consensus also reflects a "Strong Buy" rating. However, a troubling going-concern opinion from auditors and concerns regarding the performance in 'spot' mode could potentially impact its reputation.

HeartBeam has a diverse ownership structure, including institutional investors holding between 7.77% and 11.11% of the company's stock. Major institutional shareholders include Vanguard Group Inc, BlackRock, Inc., and UBS Group AG. Individual ownership is also significant, with insiders holding approximately 14.40% to 23.8% of the company. Mark E. Strome is the largest individual shareholder. Retail investors collectively own a substantial 74.50% of HeartBeam.